Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Raisman

Showing results (11-20 of 105) with videos related to

Pageof 11
Sort By:
European Journal of Pharmacology|March 1, 1979
High-affinity 3H-imipramine binding in rat cerebral cortexR Raisman, M Briley, S Z Langer
European Journal of Pharmacology|February 1, 1980
Specific tricyclic antidepressant binding sites in rat brain characterised by high-affinity 3H-imipramine bindingR Raisman, M S Briley, S Z Langer
European Journal of Pharmacology|May 30, 1980
Stereoselective inhibition of 3H-imipramine binding by antidepressant drugs and their derivativesS Z Langer, R Raisman, M S Briley
Drug Safety|December 20, 1999
Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?M G Murer, R Raisman-Vozari, O Gershanik
European Journal of Pharmacology|October 1, 1979
Human platelets possess high-affinity binding sites for 3H-imipramineM S Briley, R Raisman, S Z Langer
Journal De Pharmacologie|October 1, 1986
The pharmacological effects of acute and chronic clenbuterol treatments after lesions of central noradrenergic nerve terminalsH Francès, I Struck, P Simon, et al.
Journal of Neurochemistry|October 1, 1987
Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's diseaseR Cash, R Raisman, A Ploska, et al.
European Journal of Pharmacology|October 29, 1985
High and low affinity [3H]imipramine binding sites in control and parkinsonian brainsR Cash, R Raisman, A Ploska, et al.
Progress in Neurobiology|October 21, 2000
Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's diseaseM G Murer, Q Yan, R Raisman-Vozari
Biochemical Pharmacology|February 15, 1978
Role of cyclic AMP and angiotensin III in the response of toad skin to angiotensin IIA Coviello, R Raisman, G Elso, et al.
Pageof 11

Showing results (11-20 of 105) with videos related to

Sort By:
Pageof 11
European Journal of Pharmacology|March 1, 1979
High-affinity 3H-imipramine binding in rat cerebral cortexR Raisman, M Briley, S Z Langer
European Journal of Pharmacology|February 1, 1980
Specific tricyclic antidepressant binding sites in rat brain characterised by high-affinity 3H-imipramine bindingR Raisman, M S Briley, S Z Langer
European Journal of Pharmacology|May 30, 1980
Stereoselective inhibition of 3H-imipramine binding by antidepressant drugs and their derivativesS Z Langer, R Raisman, M S Briley
Drug Safety|December 20, 1999
Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?M G Murer, R Raisman-Vozari, O Gershanik
European Journal of Pharmacology|October 1, 1979
Human platelets possess high-affinity binding sites for 3H-imipramineM S Briley, R Raisman, S Z Langer
Journal De Pharmacologie|October 1, 1986
The pharmacological effects of acute and chronic clenbuterol treatments after lesions of central noradrenergic nerve terminalsH Francès, I Struck, P Simon, et al.
Journal of Neurochemistry|October 1, 1987
Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's diseaseR Cash, R Raisman, A Ploska, et al.
European Journal of Pharmacology|October 29, 1985
High and low affinity [3H]imipramine binding sites in control and parkinsonian brainsR Cash, R Raisman, A Ploska, et al.
Progress in Neurobiology|October 21, 2000
Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's diseaseM G Murer, Q Yan, R Raisman-Vozari
Biochemical Pharmacology|February 15, 1978
Role of cyclic AMP and angiotensin III in the response of toad skin to angiotensin IIA Coviello, R Raisman, G Elso, et al.
Pageof 11